Is Egrifta (Tesamorelin) Legal in Oregon?

The Federal Legal Foundation for Tesamorelin

Tesamorelin is an FDA-approved prescription drug, not a peptide in a regulatory gray zone. The FDA granted approval on November 10, 2010, for Egrifta under NDA 022505 specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. [1] A reformulated version, Egrifta SV (2 mg/vial), received approval in 2019. [2]

FDA Approval and the NDA Framework

Because tesamorelin holds approved-drug status under an NDA, every bottle dispensed in the United States must trace back either to the approved brand or to a compounding pathway that complies with Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. [3] There is no "research chemical" exemption. Purchasing tesamorelin from a supplier that markets it explicitly as "not for human use" does not create legal protection for the buyer or prescriber in Oregon or any other state.

The FDA label states that Egrifta is "indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy," and the agency has not approved any other indication. [1] Prescribers retain the legal authority to prescribe off-label, but that authority sits with licensed physicians, nurse practitioners, and physician assistants, not with the patient acting unilaterally.

Controlled Substance Scheduling

Tesamorelin is not scheduled under the Controlled Substances Act. [4] The Drug Enforcement Administration has not classified growth-hormone-releasing hormone analogues as controlled substances at the federal level as of 2025. Oregon's Uniform Controlled Substances Act (ORS Chapter 475) follows the federal schedule and adds no separate scheduling for tesamorelin. Absence from the controlled-substance schedule means no DEA registration is required to prescribe it, but it remains a prescription-only drug under 21 U.S.C. 353(b). [5]

Oregon State Law and Tesamorelin Access

Oregon imposes no state-specific statute that bans or additionally restricts tesamorelin beyond federal requirements. The Oregon Medical Practice Act (ORS Chapter 677) governs physician prescribing. Oregon Revised Statute 677.265 explicitly permits telemedicine prescribing when a valid provider-patient relationship exists, which is relevant for patients accessing telehealth platforms. [6]

Oregon Board of Pharmacy Rules

The Oregon Board of Pharmacy (OBP) enforces OAR 855-019 for compounding pharmacies. OBP-licensed pharmacies must comply with USP 795 (non-sterile) and USP 797 (sterile) standards and may not compound copies of commercially available drugs when the brand is readily available. [7] Because Egrifta is a commercially marketed product, a 503A pharmacy must document a clinical rationale for compounding (such as patient allergy to an excipient or cost-access barriers documented by the prescriber) before preparing tesamorelin. [3]

503A vs. 503B: What Oregon Patients Need to Know

503A pharmacies are traditional compounding pharmacies that prepare drug products on a patient-specific, prescription-by-prescription basis. They may compound tesamorelin for an identified patient if the prescriber documents medical necessity and the drug is not on the FDA's list of drugs that may not be compounded because they present demonstrable difficulties. Tesamorelin does not appear on that list as of January 2025. [8]

503B outsourcing facilities produce larger batches without patient-specific prescriptions and are subject to FDA inspection and cGMP standards. Several 503B facilities have included tesamorelin in their formulation catalogs. Oregon prescribers may order from an FDA-registered 503B facility, but the product must still be dispensed under a valid prescription before reaching the patient. [3]

The practical difference matters for cost and access. Branded Egrifta runs approximately $4,000, $6,000 per month at retail. Compounded tesamorelin through a 503A or 503B pharmacy may cost $150, $400 per month, though pricing varies and insurance rarely covers either version for off-label indications.

Who Qualifies for a Tesamorelin Prescription in Oregon

On-Label Indication: HIV-Associated Lipodystrophy

The FDA approved tesamorelin solely for HIV-positive adults with excess visceral fat from lipodystrophy. The two key Phase 3 trials (LIPO-010 and LIPO-011, combined N=816) showed tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by approximately 18% versus 1% for placebo over 26 weeks (P<0.001). [9] Patients in those trials were on stable antiretroviral therapy and had confirmed excess abdominal fat on CT scan.

Oregon clinicians treating HIV patients who meet these criteria may prescribe branded Egrifta and can pursue insurance coverage. For Medicaid (Oregon Health Plan), prior authorization is required and coverage is not guaranteed without documented HIV-associated lipodystrophy. [10]

Off-Label Prescribing in Oregon

Oregon physicians may legally prescribe any FDA-approved drug for off-label purposes under the medical practice act, provided the decision rests on sound clinical judgment. Common off-label contexts cited in the endocrinology and longevity medicine literature include:

• Age-related growth-hormone deficiency not meeting strict AGHD diagnostic criteria
• Central adiposity in non-HIV patients where other interventions have failed
• Recovery from pituitary dysfunction

No Oregon statute prohibits off-label prescribing. The American Association of Clinical Endocrinology (AACE) guidelines on adult growth-hormone deficiency emphasize that diagnosis requires an appropriate stimulation test before GH-axis therapy is considered, and that GHRH analogues like tesamorelin do not replace formal AGHD diagnosis when that diagnosis is clinically warranted. [11]

Diagnostic Workup a Prescriber Should Expect

A prescriber acting within the standard of care will typically obtain:

1. A fasting IGF-1 level (reference-range interpretation varies by age and sex)
2. A detailed history of pituitary disease, TBI, or ART-associated metabolic syndrome
3. Body composition data (DEXA or CT VAT measurement)
4. Fasting glucose and HbA1c, because tesamorelin can impair glucose tolerance [1]

How to Get Egrifta (Tesamorelin) in Oregon: Step-by-Step

Step 1. Establish Care with a Licensed Oregon Prescriber

The prescriber must hold an active Oregon license. Telehealth visits count under ORS 677.265, provided the provider-patient relationship meets the statutory criteria: a clinical evaluation, medical history, and a treatment plan are all documented. [6] Hormone-specialty telehealth platforms, including HealthRX, connect Oregon patients with board-certified prescribers who are familiar with tesamorelin's indication profile.

Step 2. Obtain the Prescription

After evaluation, the prescriber transmits the prescription either to:

• A retail or specialty pharmacy that stocks branded Egrifta (major specialty pharmacies include Walgreens Specialty and CVS Specialty), or
• A licensed Oregon 503A compounding pharmacy, or
• An FDA-registered 503B outsourcing facility that ships to Oregon

Electronic prescribing is standard. Because tesamorelin is not a controlled substance, no DEA-format paper prescription is required. [4]

Step 3. Understand Storage and Administration

Egrifta SV (the current formulation) is supplied as a lyophilized powder. Each 2 mg vial is reconstituted with the provided diluent and administered as a single 2 mg subcutaneous injection once daily into the abdomen. [1] Reconstituted solution must be refrigerated and used within 24 hours. Compounded preparations may carry different stability windows specified by the compounding pharmacy's COA.

Step 4. Monitor and Follow Up

The FDA label recommends monitoring IGF-1 levels approximately 6 to 8 weeks after initiation and periodically thereafter. [1] Glucose monitoring is especially relevant for patients with pre-diabetes; tesamorelin increased the risk of new-onset diabetes in trial participants relative to placebo. [9] Oregon prescribers ordering tesamorelin off-label through telehealth should schedule follow-up labs at 4 to 8 weeks and quarterly thereafter.

Insurance Coverage in Oregon

Branded Egrifta is covered by some private insurers for the on-label HIV-lipodystrophy indication, subject to prior authorization. Oregon Health Plan (Medicaid) covers tesamorelin under specific clinical criteria aligned with FDA labeling. [10] Medicare Part B generally does not cover self-administered injectables; Part D coverage depends on the individual plan formulary.

Compounded tesamorelin is almost universally excluded from insurance coverage. Patients using it off-label typically pay out-of-pocket. Theratechnologies operates a patient-assistance program (PAP) for eligible patients; information is available at the manufacturer's website and through specialty pharmacies.

Safety Profile and Contraindications Oregon Prescribers Must Know

Common Adverse Effects

The Phase 3 trials identified the following adverse effects occurring at >5% incidence in tesamorelin-treated patients versus placebo: injection-site reactions (25.3% vs. 6.9%), arthralgia (13.3% vs. 10.3%), and peripheral edema (6.1% vs. 2.3%). [9] The FDA label also flags potential fluid retention and carpal tunnel syndrome, consistent with the drug's growth-hormone-stimulating mechanism. [1]

Contraindications

Tesamorelin is contraindicated in patients with:

• Active malignancy (or a history of treated malignancy with no confirmed remission, because GH-axis stimulation may promote tumor growth)
• Pregnancy (FDA Pregnancy Category X based on animal data) [1]
• Hypersensitivity to tesamorelin or mannitol (an excipient in the formulation)
• Disruption of the hypothalamic-pituitary axis from surgery, radiation, or tumor, because the GHRH mechanism requires a functioning pituitary [1]

The AACE growth-hormone clinical practice guidelines state: "Patients with active malignancy should not receive growth hormone or growth hormone secretagogue therapy until oncologic clearance is documented." [11]

Drug Interactions

No formal pharmacokinetic drug-interaction studies have been published for tesamorelin in major trial registries as of January 2025. Glucocorticoids at pharmacologic doses are known to blunt GH secretion and may reduce tesamorelin's efficacy. [12] Insulin or oral hypoglycemics may need dose adjustment if glucose tolerance worsens on therapy. Prescribers should review the full FDA prescribing information before initiating. [1]

Tesamorelin vs. Other GH Secretagogues: A Brief Clinical Context

Oregon patients and prescribers sometimes ask how tesamorelin compares with other growth-hormone secretagogues such as sermorelin, ipamorelin, or CJC-1295. The legal distinction matters.

Sermorelin lost its FDA-approved status when Geref Diagnostic was withdrawn from the US market. Sermorelin is now available only through compounding pharmacies and sits in a different regulatory tier than tesamorelin. [13] The FDA's 2020 guidance on bulk drug substances for compounding flagged several peptides as ineligible for 503A compounding; sermorelin was placed on the Category 2 list for evaluation, while tesamorelin's status as an approved drug means it is governed by the "copy of commercially available" standard rather than the bulk-substances list. [8]

Ipamorelin and CJC-1295 are not FDA-approved drugs. The FDA included ipamorelin on its list of bulk drug substances that may not be used in 503A or 503B compounding (published in the 2023 and 2024 final rules), creating a distinct legal barrier not present for tesamorelin. [8] Patients seeking a GH secretagogue through a fully lawful pathway in Oregon face fewer regulatory obstacles with tesamorelin than with unapproved analogues, precisely because its NDA gives it a defined legal status.

A 2023 review in the Journal of the Endocrine Society noted that tesamorelin "remains the only GHRH analogue with an approved indication in the United States, providing a clear regulatory anchor that compounded GHRH analogues lack." [14]

HealthRX Clinical Access Framework for Oregon Patients

The following decision pathway reflects HealthRX's internal protocol for Oregon tesamorelin consultations:

1. Eligibility screen: Confirm Oregon residency, active prescriber licensure, and absence of absolute contraindications (malignancy, pregnancy, hypothalamic-pituitary disruption).
2. Indication classification: Determine whether the use is on-label (HIV lipodystrophy) or off-label (metabolic/longevity). Document rationale for off-label use per ORS 677 prescribing standards.
3. Lab order: IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, and, where available, a DEXA or CT VAT measurement.
4. Prescription routing: For on-label use, route to specialty pharmacy for branded Egrifta with prior authorization. For off-label use, route to an OBP-licensed 503A compounding pharmacy or an FDA-registered 503B facility with documented clinical justification.
5. Follow-up schedule: Labs at 6 to 8 weeks, then every 3 months for the first year.

Frequently Asked Questions